Digibind Reverses Inhibition of Cellular Rb + Uptake Caused by Endogenous Sodium Pump Inhibitors Present in Serum and Placenta of Women with Preeclampsia
Restricted accessResearch articleFirst published online February, 2011
Digibind Reverses Inhibition of Cellular Rb + Uptake Caused by Endogenous Sodium Pump Inhibitors Present in Serum and Placenta of Women with Preeclampsia
Introduction: Mechanisms mediating preeclampsia (PE) are unclear. Endogenous digitalis-like factors (EDLFs) are sodium pump (SP) inhibitors implicated in essential hypertension, but not fully explored in PE. This study asks whether EDLFs are present and increased in PE and considers their source. Methods: EDLF in sera and placentas from third trimester women with uncomplicated pregnancies or PE was assessed by a Rb+ uptake assay. A digoxin antibody Fab fragment (Digibind) known to inactivate EDLFs was also used to assess EDLFs. Results: PE serum caused significantly more SP inhibition than serum from uncomplicated pregnancies. This inhibition was concentration-dependent and reversed by Digibind. Serum from uncomplicated pregnancies showed no concentration-dependence or reversal with Digibind. Placental homogenates from control women showed little SP inhibition, but homogenates from PE women showed marked SP inhibition reversed by Digibind. Conclusion: These studies evidence EDLF in PE serum. Additionally, PE placentas have high EDLF and may represent a source.
WallisABSaftlasAFHsiaJAtrashHK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens. 2008;21(5):521–526.
2.
Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy.Am J Obstet Gynecol. 2000;183(1):S1–S22.
3.
SibaiBM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 2003;102(1):181–192.
HauthJCEwellMGLevineRJ. Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. Obset Gynecol. 2000;95(1):24–28.
6.
BuchbinderASibaiBMCaritisS. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol. 2002;186(1):66–71.
7.
HaddyFJOverbeckHW. The role of humoral agents in volume expanded hypertension. Life Sci. 1976;19(7):935–947.
8.
BlausteinMP. Sodium ions, calcium ions, blood pressure regulation and hypertension: a reassessment and a hypothesis. Am J Physiol. 1977;232(5):C165–C173.
9.
GravesSWWilliamsGH. Endogenous digitalis-like natriuretic factors. Annu Rev Med. 1987;38:433–444.
10.
HollenbergNKGravesSW. Endogenous sodium pump inhibition: current status and therapeutic opportunities. Prog Drug Res. 1996;46:9–42.
GravesSWEderJPSchryberSM. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clin Sci. 1989;77(5):501–507.
13.
BlausteinMPHamlynJMPalloneTL. Sodium pumps: ouabain, ion transport, and signaling in hypertension. Amer J Physiol. 2007;293(1):F438.
14.
SchonerWScheiner-BobisG. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism and cell growth. Am J Physiol Cell Physiol. 2007;293(2):C509–C536.
15.
NesherM. Shpolansky U, Rosen H, Lichtstein D. The digitalis-like steroid hormones: new mechanisms of action and biological significance. Life Sci. 2007;80(23):2093–107.
16.
HamlynJMBlausteinMPBovaS. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci U S A. 1991;88(14):6259–6263.
17.
GravesSWBrownBValdesRJr. An endogenous digoxin-like substances in patients with renal impairment. Ann Int Med. 1983;99(5):604–608.
18.
KrepHPriceDASoszynskiPTaoQ-FGravesSWHollenbergNK. Volume sensitive hypertension and the digoxin-like factor: reversal by an Fab directed against digoxin in DOCA-salt hypertensive rats. Am J Hypertens. 1995;8(9):921–927.
19.
KrepHHGravesSWPriceDA. Reversal of sodium pump inhibitor induced vascular smooth muscle contraction with Digibind: stoichiometry and its implications. Am J Hypertens. 1995;9(1):39–46.
20.
SmithTWLloydBLSpicerNHaberE. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon. Clin Exp Immunol. 1979;36(3):384–396.
21.
GravesSW. Sodium regulation, sodium pump function and sodium pump inhibitors in uncomplicated pregnancy and preeclampsia. Front Biosci. 2007;12:2438–2446.
22.
HickeyARWengerTLCarpenterVP. Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol. 1991;17(3):590–598.
23.
GoodlinRC. Antidigoxin antibodies in eclampsia. N Engl J Med. 1988;318(8):518–519.
24.
AdairCDBackalewVMTaylorK. Elevated endoxin-like factor complicating a second trimester pregnancy: treatment with digoxin-binding immunoglobin. Am J Nephrol. 1996;6(6):529–531.
25.
AdairCDLuperARoseJCRussellGVeilleJCBuckalewVM. The hemodynamic effects of intravenous digoxin-binding fab immunoglobulin in severe preeclampsia: a double-blind randomized, clinical trial. J Perinatolog. 2009;29(4):284–289.
26.
AdairCDBuckalewVMGravesSW. Digoxin immune Fab treatment for severe preeclampsia. Am J Perinatol. 2010;27(8):655–662.
27.
AgunanneEHorvatDUddinMNPuschettJ. The treatment of preeclampsia in a rat model employing Digibind. Am J Perinatol. 2010;27(4):299–305.
28.
HorvatDSeversonJUddinMNMitchellBPuschettJB. Resibufogenin prevents the manifestations of preeclampsia in an animal model of the syndrome. Hypertens Pregnancy. 2010;29(1):1–9.
29.
National Institutes of Health Working Group on Hypertension in Pregnancy.Classification of Hypertensive Disorders of Pregnancy. Bethesda, MD: US Dept of Health and Human Services; 1991.
30.
ZhenYFranzKBGravesSW. A novel assay of cell rubidium uptake using graphite furnace atomic absorption: application to rats on a magnesium deficient diet. J Nutr Biochem. 2005;16(5):291–296.
31.
DiamandisEPPapanastaslou-DiamandiASoldinSJ. Digoxin immunoreactivity in cord and maternal serum and placental extracts. Partial characterization of immunoreactive substances by high-performance liquid chromatography and inhibition of Na+,K+-ATPase. Clin Biochem. 1985;18(1):48–55.
32.
MorrisJFPostonLWolfeCDHiltonPJ. A comparison of endogenous digoxin-like immunoactivity and sodium transport inhibitory activity in umbilical arterial and venous serum. Clin Sci (Lond). 1988;75:577–579.
33.
HiltonPJWhiteRWLordGA. An inhibitor of the sodium pump obtained from human placenta. Lancet. 1996;348(9023):303–305.
34.
GaoSChenZXuY. The source of endogenous digitalis-like substance in normal pregnancy. Zhonghua Fu Chan Ke Za Zhi. 1998;33(9):539–541.
35.
FedorovaOVTapilskayaNIBzhelyanskyAM. Interaction of Digibind with endogenous cardiotonic steroids from preeclamptic placentae. J Hypertens. 2010;28(2):361–366.
36.
StewartLHamiltonCIngwallJ. Vascular smooth muscle response to ouabain: relation of tissue sodium to the contractile response. Circ Res. 1993;73(6):1113–1120.
37.
DostanicIPaulRJLorenzJNTheriaultSVan HuysseJWLingrelJB. The alpha2-isoform of Na-K-ATPase mediates ouabain-induced hypertension in mice and increased vascular contractility in vitro. Am J Physiol Heart Circ Physiol. 2005;288(2):H477–H485.
38.
LiSQEimCKirchULangRESchonerW. Bovine adrenals and hypothalamus are a major source of proscillaridin A and ouabain immunoreactivities. Life Sci. 1998;62(11):1023–1033.
39.
BagrovAYFedorovaOVDmitrievaRI. Characterization of a urinary bufodienolide Na+,K+-ATPase inhibitor in patients after acute myocardial infarction. Hypertension. 1998;31(5):1097–1103.
40.
GotoAIshiguroTYamadaK. Isolation of a urinary digitalis-like factor indistinguishable from digoxin. Biochem Biophys Res Commun. 1990;173(3):1093–1101.
41.
FedorovaOVSimbirtsevASKolodkinNI. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension. J Hypertens. 2008;26(12):2414–25.
42.
TaoQFHollenbergNKPriceDAGravesSW. Sodium pump isoform specificity for the digitalis-like factor isolated from human peritoneal dialysate. Hypertension. 1996;29(3):815–821.
43.
BagrovAYFedorovaOV. Effects of two putative endogenous digitalis-like factors, marinobufagenin and ouabain, on the Na+, K+-pump in human mesenteric arteries. J Hypertens. 1998;16(12 pt 2):1953–1958.
44.
WangYLewisDFAdairCDGuYMasonLKipikasaJH. Digibind attenuates cytokine TNFα-induced endothelial inflammatory response: potential benefit role of Digibind in preeclampsia. J Perinatol. 2009;29(3):195–200.
45.
EsplinMSFausettMBFauxDSGravesSW. Changes in the isoforms of the sodium pump in the placenta and myometrium of women in labor. Am J Obstet Gynecol. 2003;188(3):759–764.
46.
VanceCJEsplinMSHamblinSGravesSW. Alterations in uterine sodium pump abundance may contribute to the onset and progression of term and preterm labor in mice. Am J Obstet Gynecol. 2006;195(5):1407–1414.
47.
RedmanCWSargentIL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592–1594.
